Health Economics›Waldenstroem macroglobulinemia›First-line therapy

First-line therapy

Waldenstroem macroglobulinemia · 7 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ofatumumab monotherapy Variant #03	—	R 512 332	28d	~8.1 mo	—	~6	~R 3 073 989 PFS proxy · indirect	4
Thalidomide and Rituximab Variant #01	—	R 265 626	28d	—	—	~12	~R 632 638 indirect	—
FCR Variant #07	—	R 120 349	30d	~56.4 mo	—	~5	~R 361 047 PFS proxy · indirect	10
Bortezomib and Rituximab (VR) Variant #01	—	R 58 571	60d	~12.8 mo	—	~5	~R 241 048 PFS proxy · indirect	1
Cladribine and Rituximab Variant #01	—	R 48 077	21d	—	—	~6	~R 288 462 indirect	—
R-CHOP Variant #08	—	R 26 946	21d	~44.4 mo	—	~6	~R 109 868 PFS proxy · indirect	4
Thioguanine monotherapy Variant #01	—	R 6 994	28d	—	—	~2	~R 13 987 indirect	—

7 of 7 regimens shown